Opzelura

Incyte’s Phase 3b TRuE-AD4 trial results, presented at ISAD, demonstrate Opzelura’s effectiveness and safety in adult patients with moderate atopic dermatitis (AD) who had inadequate responses to topical corticosteroids or calcineurin inhibitors. Opzelura significantly improved AD clinical signs, with 70% achieving EASI75 and 61.3% achieving IGA-TS at Week 8. Patients experienced rapid itch reduction and improved quality of life. Incyte plans to file for EU approval based on these data, aiming to provide a non-steroidal alternative for AD treatment.